Document is current

Article History

Received: 1 September 2024

Accepted: 11 October 2024

First Online: 3 November 2024

Declarations

:

: Bruna de Freitas Dias, Christopher L Robinson, and Maria Dolores Villar-Martinez declare no competing interests. Sait Ashina provided consulting and teaching services and received honoraria from Allergan/AbbVie, Amgen, Biohaven Pharmaceuticals, Eli Lilly and Company, Impel NeuroPharma, Lundbeck, Novartis, Satsuma, Supernus, Percept, Teva, and Theranica. Peter J. Goadsby reports, over the last 36 months, grants from Celgene and Kallyope, and personal fees from Eon Biopharma, Abbvie, Amgen, eNeura, CoolTech LLC, Dr Reddy’s, Eli-Lilly and Company, Epalex, Linpharma, Lundbeck, Man&Science, Novartis, Pfizer, Sanofi, Satsuma, Shiratronics, and Teva Pharmaceuticals, and personal fees for advice through Gerson Lehrman Group, Guidepoint, SAI Med Partners, Vector Metric, and fees for educational materials from CME Outfitters, and publishing royalties or fees from Massachusetts Medical Society, Oxford University Press, UptoDate and Wolters Kluwer, and a patent magnetic stimulation for headache (No. WO2016090333 A1) assigned to eNeura without fee. Peter Goadsby is an Editorial Board member of Pain and Therapy. Peter Goadsby was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.